ロード中...
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
ESR1 mutations are frequently acquired in hormone-resistant metastatic breast cancer (MBC). CDK4/6 inhibition along with endocrine therapy is a promising strategy in hormone receptor-positive MBC. However, the incidence and impact of ESR1 mutations on clinical outcome in patients treated with CDK4/6...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5620144/ https://ncbi.nlm.nih.gov/pubmed/28978004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11383 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|